Country: Armenia
Language: English
Source: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
atezolizumab
F. Hoffmann-La Roche Ltd. 4303 Kaiseraugst-secondary packager
L01XC32
atezolizumab
60mg/ml
concentrate for solution for infusion
20ml glass vial
Prescription
Registered
2019-01-18
TECENTRIQ ® Atezolizumab 1. DESCRIPTION 1.1 THERAPEUTIC / PHARMACOLOGIC CLASS OF DRUG Anti-neoplastic agent, humanized immunoglobulin G1 (IgG1) monoclonal antibody. ATC code: not yet assigned 1.2 TYPE OF DOSAGE FORM Concentrate for solution for infusion 1.3 ROUTE OF ADMINISTRATION Intravenous (IV) infusion 1.4 STERILE / RADIOACTIVE STATEMENT Sterile product 1.5 QUALITATIVE AND QUANTITATIVE COMPOSITION _Active ingredient: _ atezolizumab Tecentriq is supplied as a single-use vial containing 20 ml preservative-free, colorless to slightly yellow solution, at a concentration of 60 mg/ml. Each vial contains a total of 1200 mg atezolizumab. _Excipients:_ as registered locally 2. CLINICAL PARTICULARS 2.1 THERAPEUTIC INDICATION Tecentriq is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma after prior chemotherapy or who are considered cisplatin ineligible. Tecentriq is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. 2.2 DOSAGE AND ADMINISTRATION GENERAL Tecentriq must be administered as an IV infusion under the supervision of a qualified healthcare professional. Do not administer as an IV push or bolus. Substitution by any other biological medicinal product requires the consent of the prescribing physician. The recommended dose is 1200 mg administered by IV infusion every three weeks. The initial dose of Tecentriq must be administered over 60 minutes. If the first infusion is tolerated, all subsequent infusions may be administered over 30 minutes. DURATION OF TREATMENT Patients are treated with Tecentriq until loss of clinical benefit (see section 3.1.2 Clinical / Efficacy Studies) or unmanageable toxicity. DELAYED OR MISSED DOSES If a planned dose of Tecentriq is missed, it should be administered as soon as possible, do not wait until the next planned dose. The schedule of administration should be adjusted to maintain a 3-week interval between doses. _ _ DOSE MODIFICATIONS No dose redu Read the complete document
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. NAME OF THE MEDICINAL PRODUCT Tecentriq 1,200 mg concentrate for solution for infusion. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each 20 mL vial of concentrate contains 1,200 mg atezolizumab*. After dilution (see section 6.6)_, _one mL of solution contains approximately 4.4 mg of atezolizumab. *Atezolizumab is an Fc-engineered, humanised IgG1 anti-programmed death-ligand 1 (PD-L1) monoclonal antibody produced in Chinese hamster ovary cells by recombinant DNA technology. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Concentrate for solution for infusion. Clear, colourless to slightly yellowish liquid. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC): after prior platinum-containing chemotherapy, or who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression ≥ 5% (see section 5.1). Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. Patients with EGFR activating mutations or ALK-positive tumour mutations should also have received targeted therapy before receiving Tecentriq (see section 5.1). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Tecentriq must be initiated and supervised by physicians experienced in the treatment of cancer._ _ PD-L1 testing for patients with UC Patients with previously untreated UC should be selected for treatment based on the tumour expression of PD-L1 confirmed by a validated test (see section 5.1). 3 Posology The recommended dose of Tecentriq is 1,200 mg administered intr Read the complete document